印度製藥產業市場報告書 是由出版商Espicom Business Intelligence在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 124 價格從美金1085起跳。
在醫療儀器、醫藥品市場上專門提供具有權威情報的市調公司 Espicom Business Intelligence（總公司：英國），收集了印度的相關資料後，出版調查報告書 " The Pharmaceutical Market: India - Opportunities and Challenges"。
此報告書由1) 醫藥品產業的展望 2) 背景資料 3) 醫療系統 4) 製藥市場的加入等4大項所構成。各項目的架構內容如下所示。
＜醫藥品產業的展望＞
- 當今的市場規模
- 5 年內的市場預測
- 市場展望與 SWOT 分析
- 市場架構
- 市場發展
- 主要各國資料預測
＜背景檔案＞
＜醫療系統＞
- 組織與行政
- 醫療費
- 醫院設備與業務
- 外來病患
- 醫療關係者數
＜製藥市場的加入＞
- 規範環境
- 國內主要醫藥品企業
- 樣本市場
- 醫藥品進出口的相關資料
- 國內生產
- 名冊
Abstract
The Indian pharmaceutical market is highly competitive and remains
dominated by low priced, domestically-produced generics. Despite having the
second largest population in the world and a growing middle class with high
healthcare expectations, India accounts for less than 2% of the world
pharmaceutical market in value terms. In one of the world's better performing
economies, spending on pharmaceuticals accounts for less than 1% of GDP and
average per capita spending remains one of the lowest levels in the region.
India's biopharmaceutical sector is currently experiencing double digit
growth and this is expected to continue, driven by the vaccines market. Growth
drivers include education and increased awareness of disease prevention,
increases in disposable income and government participation in immunisation
programmes. Continued growth is also expected in the diagnostic and
therapeutic segments, including cancer and diabetes. India is already known as
the diabetic capital of the world and the number of diabetes patients in India
is expected to grow to 70 million by 2025. Cancer therapies are also lucrative
for many Indian companies due to high unmet need, increased awareness and the
comparative affordability of domestically produced drugs.
The Indian pharmaceutical industry is responsible for around 8% of
world pharmaceutical production. Over the last few years, a number of Indian
companies have been targeted for foreign acquisition. Concerns have been
raised that this trend could adversely affect generic drug prices in India.
The Ministry of Health wants safeguards built into the Foreign Direct
Investment process amid fears that continued foreign acquisitions will
adversely affect the domestic industry and push prices up, thereby potentially
undermining the government's efforts to make generic drugs affordable. This
could lead to essential medicines becoming more expensive and adversely
affecting public health programmes.
During 2011, in May Par Pharmaceutical Companies entered into a definitive
agreement to acquire privately-held Edict Pharmaceuticals, a Chennai-based
developer and manufacturer of solid oral dosage generics. In April, Hikma
Pharmaceuticals announced that it had agreed to acquire a minority interest in
Unimark Remedies, is a privately-held Indian manufacturer of active
pharmaceutical ingredients and API intermediaries. Over the last few years a
number of Indian businesses have been partially or fully acquired by
international companies, notably Dabur Pharma (Fresenius Kabi), Matrix
Laboratories (Mylan), Ranbaxy (Daiichi Sankyo), Orchid's generic formulations
(Hospira) and Piramal's domestic formulations business (Abbott).
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been
redesigned to provide enhanced strategic intelligence in a user-friendly
format. Each report provides in-depth information, setting the pharmaceutical
market in context.
The reports provide:
- Five-year projections for economic, demographic, health expenditure,
health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence
Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health
infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest
information for a full year. In addition, the service will keep you up to date
with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health
expenditure, hospital and primary care infrastructure & services and
healthcare personnel, is additionally included.
Report Statistics
- Publication Date: October 31st 2011
- Total Number of Pages: 124
- Formats: Web, PDF and Paper
Table of Contents
EXECUTIVE SUMMARY
- Snapshot: Strategic Espicom Analysis
- Snapshot: Key Data Projections
MACROENVIRONMENT
- POLITICAL
- ECONOMIC
- LEGAL
- Background to Pharmaceutical Patents
- Mashelkar Committee Report, December 2006
- The Patents (Amendments) Bill, 2005
- Compulsory Licensing
- Pre- & Post-Grant Opposition
- Mailbox Applications
- Other Issues
- The Patents (Amendment) Rules, 2006
- Previous Patents Act Amendments and Exclusive Marketing Rights
- Challenges and Patent Decisions in the Indian High Courts
- Novartis Once Again Challenges the Indian Patents Act
- Bayer's Patent Plea for Cancer Drug Rejected by Indian High Court
- US Special 301 Report - India Remains on Priority Watch List
- DEMOGRAPHIC
- Population
- Demographic Indicators
- Births
- Deaths
- Infant Mortality
- Life Expectancy at Birth
EPIDEMIOLOGY
- DISEASE BURDEN
- Leading Causes of Mortality
- DISEASE PREVALENCE
- Communicable Diseases
- HIV/AIDS
- Leprosy
- Tuberculosis
- Vector Borne Diseases
- Non-Communicable Diseases
- Blindness
- Cancer
- Diabetes, Cardiovascular Disease and Stroke
- National Rural Health Mission
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
- ORGANISATION
- Department of Health and Family Welfare
- Department of AYUSH
- Health Insurance
- EXPENDITURE
- Projections
- Latest Figures
- INFRASTRUCTURE
- Hospital Infrastructure
- Private Hospitals and Clinics
- Apollo Hospitals Group
- Fortis Healthcare
- Max Healthcare
- Wockhardt Hospitals
- Other Commercial Providers
- Ambulatory Infrastructure
- Primary Care
- First Aid and Disaster Relief
- Healthcare for the Underprivileged, Scheduled Castes and Scheduled
Tribes
- WORKFORCE
- Projections
- Latest Figures
REGULATORY AFFAIRS
- NATIONAL AUTHORITY
- REGULATORY DEVELOPMENTS
- National Pharmaceuticals Policy, 2006
- MARKETING REGISTRATION
- DGCI Set to Co-ordinate Drug Approvals
- PROMOTION
PRICING
- Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
- Drug Price Control Review Committee
- US Pharma Industry Concerns
DISTRIBUTION CHANNELS
- Medical Stores Organisation
- Pharmacy Chains
- Apollo Pharmacy
- Guardian Pharmacy
- Religare Wellness
- 98.4
MARKET ANALYSIS
- SIZE
- Projections
- Historical Figures
- Current Structure
- PRODUCT DEVELOPMENT
- Traditional Indian Medicines
- MANUFACTURING
- TRADE
- Exports
- Imports
- Balance of Trade
COMPETITION
- Foreign Direct Investment in the Pharmaceutical Industry under Review
- TRADE ASSOCIATIONS
- TRADE FAIRS
- Bangalore Bio 2012
- India Chem 2012
- Pharma World EXPO
COMPANY INTELLIGENCE
- Foreign private producers
- Abbott
- Actavis
- Daiichi Sankyo
- GlaxoSmithKline
- Mylan
- Pfizer India
- Sanofi
- Local Private Producers
- Alembic Ltd.
- Aurobindo Pharma
- Cipla Ltd.
- Claris Lifesciences
- Dr. Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals
- Jubilant Life Sciences
- Lupin Limited
- Natco Pharma
- Orchid Chemicals & Pharmaceuticals Ltd.
- Piramal Healthcare
- Ranbaxy Laboratories
- Strides Arcolab
- Sun Pharma
- Torrent Pharmaceuticals
- Wockhardt Ltd.
- Zydus Cadila
- COMPETITIVE STRATEGIES
- Joint Venture
- Recent Acquisitions & Divestitures
- Agreements
BIOLOGICS & BIOSIMILARS
- COMPETITION
- Company Intelligence
- Avesthagen
- BCG Vaccine Laboratory, Chennai
- Biocon
- Cipla
- Claris Lifesciences
- Dr Reddy's
- Glenmark Pharmaceuticals
- Lupin
- Panacea Biotec
- Ranbaxy/Daiichi Sankyo
- Wockhardt
- Zydus Cadila
CONCLUSIONS: OPPORTUNITIES & CHALLENGES
- Strategic Espicom Analysis
- MACROENVIRONMENT
- EPIDEMIOLOGY
- HEALTHCARE
- REGULATORY AFFAIRS
- PRICING & REIMBURSEMENT
- DISTRIBUTION CHANNELS
- MARKET
- COMPETITION
- OTC PHARMACEUTICALS
- GENERICS
- BIOLOGICS & BIOSIMILARS
DIRECTORY
- GOVERNMENT ORGANISATIONS
- PHARMACEUTICAL COMPANIES
- TRADE ASSOCIATIONS
LIST OF TABLES
- Espicom Analysis of the Pharmaceutical Market, 2011
- Key Data Projections, 2011-2016
- Political Landscape, 2011
- Regional Ranking of Projected Economies, 2016
- Projected Economy, 2011-2016
- Regional Ranking of Projected Demographics, 2016
- Projected Demographics, 2011-2016
- Summary of Demographic Data
- Demographic Indicators, 2000-2008
- Reported Incidence of Vaccine Preventable Diseases, 2008-2009
- Regional Ranking of Projected Health Expenditure, 2016
- Projected Health Expenditure, 2011-2016
- Health Expenditure, 2010
- Regional Ranking of Projected Physicians, 2016
- Projected Physicians, 2011-2016
- Doctors Registered with State Medical Councils, 2007-2009
- Regional Ranking of Projected Pharmaceutical Markets, 2016
- Projected Pharmaceutical Market at Retail Prices, 2011-2016
- Historical Pharmaceutical Market at Retail Prices, 1995-2010 (US$ Milllion)
- Pharmaceutical Exports by Category, 2005-2009 (US$000s)
- Leading Destinations of Pharmaceuticals, 2009 (US$000s)
- Pharmaceutical Imports by Category, 2005-2009 (US$000s)
- Imports of Raw Materials by Country/Region, 2009 (US$000s)
- Imports of Antisera & Vaccines by Country/Region, 2009 (US$000s)
- Imports of Semi-finished Medicaments by Country/Region, 2009 (US$000s)
- Imports of Medicaments by Country/Region, 2009 (US$000s)
- Balance of Pharmaceutical Trade, 2005-2009 (US$000s)
- Foreign Acquisitions of Indian Pharmaceutical Companies, 2007-2011
- Alembic: Financial Results, 2007-2011
- Alembic: Manufacturing Facilities
- Aurobindo Pharma: Financial Results, 2007-2011
- Aurobindo Pharma: Manufacturing Facilities
- Cipla: Financial Results, 2007-2011
- Cipla: Manufacturing Facilities
- Dr. Reddy's: Financial Summary, 2007-2011
- Dr. Reddy's: Manufacturing Facilities
- Glenmark: Financial Results, 2007-2011
- Glenmark: Manufacturing Facilities
- Jubilant Life Sciences: Financial Results, 2010-2011
- Lupin: Financial Results, 2007-2011
- Lupin: Manufacturing Facilities
- Natco Pharma Financial Results, 2007-2011
- Orchid: Financial Results, 2007-2011
- Orchid's Top-10 Brands
- Orchid: Manufacturing Facilities
- Piramal Healthcare: Financial Results, 2007-2011
- Piramal Healthcare: Manufacturing Facilities
- Ranbaxy: Financial Results, 2006-2010
- Ranbaxy: Manufacturing Facilities
- Strides: Financial Results, 2006-2010
- Sun Pharma: Financial Results, 2007-2011
- Sun Pharma: Manufacturing Facilities
- Torrent Pharma: Financial Results, 2007-2017
- Wockhardt: Financial Results, 2006-2011
- Wockhardt Manufacturing Facilities
- Zydus Cadila: Financial Results, 2007-2011
- Zydus Cadila: Manufacturing Facilities
- Biocon: Financial Results, 2007-2011
- Panacea Biotec: Financial Results, 2007-2011
- Espicom Analysis of the Pharmaceutical Market, 2011
- SWOT Analysis of the Pharmaceutical Market, 2011
LIST OF CHARTS
- Population by Age Group (%)*
- Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail
Prices, 2016
- Regional Comparison of Projected Pharmaceutical Market Share, 2016
- Historical Pharmaceutical Market at Retail Prices, 1995-2010
- Pharmaceutical Exports, 1999-2009 (US$ Millions)
- Change in Pharmaceutical Exports, 2005-2009 (%)
- Pharmaceutical Exports by Destination, 2009 (%)
- Pharmaceutical Imports, 1999-2009 (US$ Millions)
- Change in Pharmaceutical Imports, 2005-2009 (%)
- Pharmaceutical Imports by Country/Region, 2009 (%)
- Pharmaceutical Balance of Trade, 1999-2009 (US$ Billions)
- Radar Graph of the Pharmaceutical Market, 2011
|
